(Q41262871)

28 September 2017

1 reference

title

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses (English)

1 reference

28 September 2017

0 references

Tseng S

1

1 reference

28 September 2017

Pak G

2

1 reference

28 September 2017

Washenik K

3

1 reference

28 September 2017

Pomeranz MK

4

1 reference

28 September 2017

Shupack JL

5

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 December 1996

1 reference

Journal of the American Academy of Dermatology

28 September 2017

1 reference

28 September 2017

35

1 reference

28 September 2017

969-979

1 reference

28 September 2017

6

1 reference

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

28 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide and congeners as anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide for autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

PROLONGATION OF SKIN HOMOGRAFT SURVIVAL BY THALIDOMIDE.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Inhibition of PMN leukocytes chemotaxis by thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide Therapy for Inflammatory Dermatoses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in the treatment of actinic prurigo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Polymorphous light eruption: Treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Actinic prurigo (Hutchinson's summer prurigo)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in actinic prurigo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Cellular immune effects of thalidomide in actinic prurigo

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Treatment of discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Significant response of oral aphthosis to thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in severe orogenital ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Sutton's disease (periadenitis mucosa necrotica recurrens).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in hyperalgic pharyngeal ulceration of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide to treat esophageal ulcer in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in the treatment of Behçet's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide effects in Behçet's syndrome and pustular vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide for graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide for graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide treatment for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide a promising new treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Pure cutaneous histiocytosis resembling sinus histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Remission of Langerhans cell histiocytosis with thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide for recurrent erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in Weber-Christian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Treatment of ulcerative colitis with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide in painful AIDS-associated proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide therapy. An open trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide--a therapy for the immunological consequences of HIV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Proposed mechanisms of action in thalidomide embryopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

A quantitative ultrastructural study of motor and sensory lumbosacral nerve roots in the thalidomide-treated rabbit fetus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Development of polyneuropathy during thalidomide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide neuropathy: an electrophysiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide, peripheral neuropathy and AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Erythroderma due to thalidomide: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

Thalidomide hypersensitivity in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990122-X

7 January 2021

10.1016/S0190-9622(96)90122-X

Identifiers

DOI

1 reference

28 September 2017

1 reference